NURO VS HOTH Stock Comparison
Performance
NURO10/100
10/100
NURO returned -70.24% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
HOTH10/100
10/100
HOTH returned -72.17% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
NURO63/100
63/100
2 analysts offer 12-month price targets for NURO. Together, they have an average target of 0, the most optimistic target put NURO at 0 within 12-months and the most pessimistic has NURO at 0.
HOTH
"Analyst Price Targets" not found for HOTH
Technicals
NURO36/100
36/100
NURO receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
HOTH11/100
11/100
HOTH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
NURO100/100
100/100
NURO has missed earnings 0 times in the last 20 quarters.
HOTH10/100
10/100
HOTH has missed earnings 12 times in the last 20 quarters.
Profit
NURO10/100
10/100
Out of the last 20 quarters, NURO has had 1 profitable quarters and has increased their profits year over year on 0 of them.
HOTH10/100
10/100
Out of the last 20 quarters, HOTH has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
NURO51/100
51/100
NURO has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
HOTH57/100
57/100
HOTH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.
Sentiment
NURO
"Sentiment" not found for NURO
HOTH68/100
68/100
HOTH had a bullish sentiment score of 68.41% across Twitter and StockTwits over the last 12 months. It had an average of 1.50 posts, 0.10 comments, and 0.30 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
NeuroMetrix, Inc. Common Stock Summary
Nasdaq / NURO
Healthcare
Medical - Devices
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Hoth Therapeutics, Inc. Common Stock Summary
Nasdaq / HOTH
Healthcare
Biotechnology
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare NURO to other companies in the same or a similar industry.